StreetInsider.com News Articles

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

East Hanover, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Thu, 07 May 2026 09:00:00 -0400

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US
Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing

Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor

Thu, 30 Apr 2026 12:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26404287.html

Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor

Thu, 30 Apr 2026 12:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26404287.html

Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor

Thu, 30 Apr 2026 12:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26404287.html

Novartis completes seventh US facility plan with North Carolina site

Thu, 30 Apr 2026 07:01:06 -0400

Novartis announced plans for a new active pharmaceutical ingredient manufacturing facility in Morrisville, North Carolina, completing its commitment to add seven new US facilities within one year of its $23 billion US investment plan.

The 56,200-square-foot facility will produce APIs for solid dosage tablets, capsules and RNA therapeutics. This marks Novartis's fifth facility in North Carolina across three sites and aims to establish end-to-end US manufacturing capability from active ingredients through finished medicines.

"Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,"

Novartis completes seventh US facility plan with North Carolina site

Thu, 30 Apr 2026 07:01:06 -0400

"Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,"

Novartis completes seventh US facility plan with North Carolina site

Thu, 30 Apr 2026 07:01:06 -0400

"Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,"

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Thu, 30 Apr 2026 07:00:00 -0400

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

East Hanover, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics. The facility represents a critical step that will strengthen end‑to‑end US production capability from active ingredients

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Thu, 30 Apr 2026 07:00:00 -0400

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Thu, 30 Apr 2026 07:00:00 -0400

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history